Amgen and ShanghaiTech University announce plans for Amgen China R&D center
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) and ShanghaiTech University today announced the two organizations have entered into a memorandum of understanding (MOU) to form a strategic partnership for the advancement of biopharmaceutical discovery and translational research in China. This agreement includes plans for Amgen to open a China research and development (R&D) center at ShanghaiTech University.
Malaria No More and Novartis launch Power of One, a global digital fundraising campaign to help eliminate malaria deaths
- Details
- Category: Novartis
Novartis and Malaria No More announced today the debut of the Power of One campaign, encouraging people around the world to help end child deaths from malaria. Novartis will support the campaign financially and donate up to three million Coartem® Dispersible treatments to match antimalarials funded by the public.
GSK signs a multi-year agreement with BARDA to supply the US government with anthrax treatment
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) plc has announced a new four year contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services (HHS), for the provision of its inhalation anthrax treatment, raxibacumab. The US government is purchasing the medicine as a counter measure against a potential bioterrorist attack.
Novartis marks World CML Day with update on global research program to evaluate whether Ph+ CML patients can live treatment-free
- Details
- Category: Novartis
Novartis commemorates World CML Day by announcing the latest milestone in its unique clinical trial program evaluating the potential for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) to maintain undetectable levels of disease after stopping drug therapy - a concept called treatment-free remission. More than 100 study sites are now enrolling patients to the trial program.
Bayer fights Chagas disease in Argentina together with Caritas
- Details
- Category: Bayer
The Bayer Cares Foundation and Caritas Argentina have laid the foundation for a new project to combat the Chagas disease in Argentina. Chagas disease is still an indication with a high unmet medical need because the minor, flu-like symptoms are rather non-specific and therefore often misinterpreted.
Christoph Franz nominated to become new Roche Chairman
- Details
- Category: Roche
At the forthcoming Annual Shareholders Meeting on 4 March 2014, the Roche Board of Directors will propose Christoph Franz to be elected as Chairman of the Board. Christoph Franz is thus nominated to succeed Franz B. Humer, who announced at the last shareholder meeting that he would not be standing for re-election.
AstraZeneca and Merck enter licence agreement for investigational oral WEE1 kinase inhibitor therapy for cancer
- Details
- Category: AstraZeneca
AstraZeneca announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune, a privately-held, Maryland, US-based biologics company focused on developing novel therapeutics in cancer immunology.
More Pharma News ...
- Novartis announces an exclusive global licensing and research collaboration with Regenerex
- Pradaxa® (dabigatran etexilate) drives Boehringer Ingelheim's innovation promise in cardiovascular diseases
- Onglyza® (saxagliptin) achieves primary safety endpoint in SAVOR cardiovascular outcomes trial
- Novartis holds annual healthcare entrepreneur competition
- Nexavar® (sorafenib) granted priority review for differentiated thyroid cancer in the U.S.
- Amgen to acquire Onyx Pharmaceuticals for $125 per share in cash
- MedImmune strengthens immune-mediated cancer therapy portfolio with acquisition of Amplimmune